|
1
|
Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.
|
Haematologica
|
2013
|
0.89
|
|
2
|
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
|
Biol Blood Marrow Transplant
|
2010
|
0.86
|
|
3
|
Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.
|
Clin Lymphoma Myeloma
|
2009
|
0.84
|
|
4
|
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.82
|
|
5
|
Gene expression profiling of acute graft-vs-host disease after hematopoietic stem cell transplantation.
|
Exp Hematol
|
2012
|
0.79
|
|
6
|
Autologous hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: still not out of fashion.
|
Ann Hematol
|
2009
|
0.78
|
|
7
|
Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide.
|
Exp Hematol
|
2009
|
0.77
|
|
8
|
Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia.
|
Am J Hematol
|
2015
|
0.77
|
|
9
|
Skin lesions induced by bortezomib.
|
Haematologica
|
2005
|
0.77
|
|
10
|
Transmission of t(11;14)-positive cells by allogeneic stem cell transplant: 10-year journey to mantle cell lymphoma.
|
Leuk Lymphoma
|
2014
|
0.76
|
|
11
|
Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy.
|
Hematol J
|
2005
|
0.76
|
|
12
|
Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
|
Exp Hematol
|
2009
|
0.76
|
|
13
|
Evaluation of response in hepatitic variant of acute liver graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2010
|
0.75
|